** Shares of drug developer Keros Therapeutics fall 10.26% to $11.20 premarket
** Co says it has voluntarily halted all dosing in a mid-stage trial due to safety concerns
** Adds is terminating the trial early, and patients are expected to be monitored through the end-of-trial visits
** The mid-stage trial was studying its experimental drug cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, a rare lung condition that causes high blood pressure in the pulmonary arteries
** Earlier in Dec., co halted the 3.0 mg/kg and 4.5 mg/kg treatment based on the observation of pericardial effusions, build up of fluids around the heart, at those dose levels
** Co has notified investigators and certain regulatory authorities, including the FDA, about this decision, and is in the process of notifying other relevant regulatory authorities
** Stock fell ~60% last year
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。